Return to Listing

3 result(s) for TREANDA

PI Name Protocol # Title
Alexey Danilov IRB00011620 A Phase II, Open-Label Study Of Obinutuzumab Plus Bendamustine (BG) In Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Stephen Spurgeon IRB00011800 Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Alexey Danilov STUDY00015069 A randomized phase III study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib alone in untreated older patients (≥ 65 years of age) with Chronic Lymphocytic Leukemia (CLL)
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080